Dr Lidofsky’s clinical and translational research spans the spectrum of disorders of the liver, from pathophysiology to disease management. He is particularly interested in developing technologies that overcome barriers to liver disease screening and application of evidence-based treatments, in domains that range from hepatitis C hepatocellular carcinoma, and he maintains a robust clinical investigation program in the area of nonalcoholic fatty liver disease.
Cirrhosis, hepatitis C, hepatocellular carcinoma, nonalcoholic fatty liver disease
View all publications.
Alexander KS, Zakai NA, Lidofsky SD, Callas PW, Judd SE, Tracy RP, Cushman M. 2018. Non-alcoholic fatty liver disease, liver biomarkers and stroke risk: The Reasons for Geographic and Racial Differences in Stroke cohort. PLOS One 10:e0123490
Everett BT, Lidofsky SD. 2018. Adherence to surveillance endoscopy following hospitalization for index esophageal variceal hemorrhage. World J Gastrointest Surg 10:40-48
MacLean CD, Berger C, Cangiano ML, Ziegelman D, Lidofsky SD. 2018. Impact of electronic reminder systems on hepatitis C screening in primary care. J Viral Hepat 25:939-944
VanOpdorp JR, Ferrentino N, Strader DB, Lidofsky SD. 2019. Utility of laboratory monitoring during hepatitis C treatment with ribavirin-free direct acting antiviral regimens. J Viral Hepat 26:778-781
Training
Ph.D. 1980, Columbia University of New York, Chemistry
M.D. 1982, Columbia University of New York, Medicine
Residency, 1985, University of Colorado Health Sciences Center
Chief Resident, 1986, University of Colorado Health Sciences Center
Fellowship, 1990, University of California, Gastroenterology